Incyte Stock (NASDAQ:INCY)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$67.49

52W Range

$50.27 - $70.36

50D Avg

$64.39

200D Avg

$60.39

Market Cap

$12.83B

Avg Vol (3M)

$2.05M

Beta

0.73

Div Yield

-

INCY Company Profile


Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2,524

IPO Date

Nov 04, 1993

Website

INCY Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Product$2.75B$2.07B-
J A K A F I$2.74B--
M I N J U V I$19.65M--
Milestone And Contract Revenue$165.00M$205.00M-
Olumiant Royalty$134.55M$110.92M-
OPZELURA$128.74M$4.91M-
Milestone and contract revenues$165.00M$95.00M-
I C L U S I G$105.84M$105.00M-
Royalty$482.74M$392.97M-
PEMAZYRE Royalty Revenues$84.65M--
Tabrecta Royalty Revenues$15.41M$4.14M-
TABRECTA Royalty Revenues-$10.39M-
Product royalty revenues-$569.25M-
MINJUVI-$68.53M-
PEMAZYRE-$109.39M-
Product revenues, net-$2.32B-
ICLUSIG-$4.67M-
JAKAVI Royalty Revenues-$337.99M-
OLUMIANT Royalty Revenues-$220.88M-
Pemazyre--$25.88M
Jakavi Royalty Revenues--$277.90M

Fiscal year ends in Dec 23 | Currency in USD

INCY Financial Summary


Dec 23Dec 22Dec 21
Revenue$3.70B$3.39B$2.99B
Operating Income$620.52M$579.44M$585.78M
Net Income$597.60M$340.66M$948.58M
EBITDA$904.74M$631.52M$611.16M
Basic EPS$2.67$1.53$4.30
Diluted EPS$2.65$1.52$4.27

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Jul 30, 24 | 11:29 AM
Q1 24Apr 30, 24 | 12:00 AM
Q4 23Feb 13, 24 | 12:37 PM

Peer Comparison


TickerCompany
IONSIonis Pharmaceuticals, Inc.
ARWRArrowhead Pharmaceuticals, Inc.
DNLIDenali Therapeutics Inc.
APLSApellis Pharmaceuticals, Inc.
SRPTSarepta Therapeutics, Inc.
BGNEBeiGene, Ltd.
BMRNBioMarin Pharmaceutical Inc.
ALNYAlnylam Pharmaceuticals, Inc.
RXDXPrometheus Biosciences, Inc.
ACADACADIA Pharmaceuticals Inc.
AXSMAxsome Therapeutics, Inc.
HRMYHarmony Biosciences Holdings, Inc.
UTHRUnited Therapeutics Corporation
FOLDAmicus Therapeutics, Inc.
RAREUltragenyx Pharmaceutical Inc.
ARGXargenx SE